Back to NEWS

The MedSIR Project Development team attended the 2019 Genitourinary (GU) Cancers Symposium held in San Francisco, CA on February 14-16. It was a great opportunity to meet our scientific collaborators, business partners, and friends, and catch up with the latest news and developments in the genitourinary cancer space.

Highlights of this year麓s ASCO GU include:

    • Final analysis of the LATITUDE phase III study was presented. Treatment with abiraterone acetate and prednisone with androgen deprivation therapy (ADT) in men with newly-diagnosed, castration sensitive, metastatic prostate cancer continues to demonstrate a significant OS advantage than ADT alone.
    • Efficacy and safety data of the ARAMIS study, which looks at darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC), was presented. Based on these results, darolutamide appears safe and effective for men with nmCRPC, increasing both metastasis-free survival and overall survival at this interim analysis. Darolutamide will be the third drug to join the nmCRPC space, along with apalutamide and enzalutamide.
    • Data from the phase 3 ARCHES trial shows that enzalutamide significantly improved radiographic progression-free survival in men with metastatic hormone-sensitive prostate cancer.
    • The JAVELIN Renal 101 subgroup analysis demonstrated longer PFS and higher ORR with avelumab plus axitinib compared to sunitinib for treatment-na茂ve patients with advanced RCC.
    • Treatment with chemotherapy and radiotherapy after surgery improves disease free survival and overall survival in advanced urothelial carcinoma as demonstrated by results from a randomized phase III trial of adjuvant sequential chemotherapy plus radiotherapy versus adjuvant radiotherapy alone for locally advanced bladder cancer after radical cystectomy.

ASCO GU 2019 was a great, successful meeting and we can麓t wait till next year to see what new advances in the treatment of genitourinary cancers are presented! These are indeed exciting times!

Share (and comment) this content

Back to NEWS